OBJECTIVES: To compare treatment satisfaction (TS) associated with insulin administration in type 2 diabetes subjects treated with either insulin glargine based regimens or Neutral Protamine Hagedorn (NPH) insulin based regimens for at least 6 months. METHODS: As part of a comparative, non-interventional, multi-centre, cross-sectional study in a primary care setting in Germany, patients with insulin-dependent type 2 diabetes completed the Insulin Treatment Experience Questionnaire (ITEQ), a new condition-specific instrument assessing TS, and the Diabetes Treatment Satisfaction Questionnaire (DTSQs). The ITEQ contained 28 items among seven subscales (leisure activities, psychological barriers, handling, diabetes control, dependence, weight control, sleep); forming an ITEQ total score transformed as 0 to 100, with 100 indicates high treatment satisfaction. To examine differences between the two treatment groups Mann-Whitney U tests were used. Multivariate linear regression models were performed to determine differences between treatment groups, controlling for sociodemographic and diabetes-related characteristics, respectively. RESULTS: Overall, 1858 individuals were enrolled in the study, and TS analyses were conducted with data from the 1,602 per protocol patients (982 insulin glargine and 620 NPH insulin). Demographic data of patients receiving either insulin glargine or NPH insulin were similar. DTSQs satisfaction score, ITEQ subscales and ITEQ total score differed between therapy regimens and were significantly higher in the insulin glargine group (DTSQs: 29.9±5.5 vs. 29.2±5.7, p=0.01; ITEQ total score: 71.5±13.1 vs. 67.6±13.9, p<0.001). Results of the regression models indicate that differences between the groups were stable after adjustment. CONCLUSIONS: Our results indicate that insulin glargine was associated with significant higher treatment satisfaction compared to NPH insulin among patients with type 2 diabetes. The results suggest that the use of insulin glargine provide an additional treatment benefit for type 2 patients with insulin dependent diabetes mellitus.